All articles by GlobalData



Tilsotolimod combo’s trial failure leaves refractory melanoma patients in limbo

Idera Pharmaceuticals has revealed that the Phase III, pivotal ILLUMINATE-301 trial of tilsotolimod in combination with Bristol Myers Squibb’s Yervoy (ipilimumab) versus Yervoy alone in patients with anti-programmed death protein-1 (anti-PD-1)-refractory advanced melanoma did not meet its co-primary endpoint of objective response rate (ORR).

Chinese checkpoint inhibitors are poised to change global IO markets

The Chinese Government’s significant R&D investments in recent years has resulted in the successful commercialisation and launch of several domestically developed therapeutic agents.

Turning point: November marked by promising Covid-19 vaccine development data

With the global devastation of Covid-19 continuing into 2021, the month of November marks a turning point in the pandemic timeline. A number of sponsors have released Phase III vaccine trial results in this month with all vaccines displaying good efficacy and generally well-tolerated safety profiles

Jardiance fails to deliver in EMPERIAL trials for heart failure

The trial failure places doubt on the success of Jardiance in further trials for HF-REF and HF-PEF and may impact the uptake of the drug.

Astellas expands into gene therapy with $3bn acquisition of Audentes

The acquisition of Audentes will allow Astellas to expand into a fifth primary focus area: genetic regulation.

Evaluating NICE guidelines in regards to cannabis-based medicinal products targeting pain

Campaigners argue the new regulations are not extensive enough where the recommendation of cannabis-based medicine for pain is concerned.

IDWeek 2019: Long-acting antiretroviral therapy shows promise for HIV patients with low adherence

HIV infections can be well controlled with antiretroviral therapy to a degree where the viral load is not detectable anymore.

Global Blood Therapeutics leads in world sickle cell disease trials

Sickle cell disease comprises a group of inherited disorders caused by mutations of haemoglobin subunit beta.

Trends in clinical trials for gene therapies in neurology

84% of gene therapy trials happening in various neurology indications, listed in GlobalData’s Pharma Intelligence Center, are in early-stage development, that is Phase I, Phase I/II, and Phase II. 

Top ten drugs in biosimilar trials globally

The number one drug in biosimilar clinical trials by count is adalimumab biosimilar, referencing the branded biologic Humira.